The Incretin Revolution: How Established and Emerging Incretin Therapies Fit into Treatment Strategies for Patients with Type 2 Diabetes, Obesity and Metabolic Comorbidities

FACULTY PRESENTERS

Guillermo E. Umpierrez, MD, CDCES, FACE, MACP
Professor of Medicine
Emory University
President for Medicine and Science
American Diabetes Association
Atlanta, GA

Prof. Dr. med. Dr. h. c. Michael A. Nauck
St.Josef- Hospital Bochum (GER)
Ruhr- University-Bochum
Head of Clinical Research (Section Diabetology)
Bochum, Germany

PROGRAM OVERVIEW

This activity features education regarding the links between obesity and diabetes, the role of the incretin system in these metabolic disorders, and use of incretin therapies to manage diabetes-related obesity.

TARGET AUDIENCE

This educational activity is intended for endocrinologists who treat patients with T2DM globally.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Determine which patients with T2DM are poised to benefit from earlier treatment intensification to achieve optimal glycemic and metabolic outcomes
• Assess the safety, efficacy, and mechanisms of GIP/GLP-1 receptor agonists
• Explain the potential role of GIP/GLP-1 receptor agonists in the treatment of patients with T2DM
• Implement a shared decision making approach to help patients with T2DM achieve and maintain weight loss for more optimal outcomes

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

EUROPEAN CREDIT DESIGNATION STATEMENT

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at [email protected].

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetes-related obesity.
CNE Credits: 1.25 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.25 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Guillermo E. Umpierrez, MD

Dr. Umpierrez reports that Emory University receives research funds from the NIH (NATS and NIDDK), Dexcom, Bayer, Abbott and Astra Zeneca.

Michael A. Nauck, MD

Dr. Nauck has been member on advisory boards or has consulted with Boehringer Ingelheim, Eli Lilly & Co., Menarini/Berlin Chemie, Merck, Sharp & Dohme, NovoNordisk, Regor, and ShouTi Inc./Gasherbrum. He has received grant support from AstraZeneca, Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and NovoNordisk. He has also served on the speakers’ bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Medscape, Medical Learning Institute, Menarini/Berlin Chemie, Merck, Sharp & Dohme, NovoNordisk, and Sun Pharma.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
• Debra Gordon, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
• Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
• Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
• Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
• Rashado Coote, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASED DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.